ArticleInternational journal of clinical and experimental pathology2018
Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Mismatch repair deficiency and its relationship with histopathological features in gastric cancer patients.Nagoya journal of medical science · 2025Article
- Clinicopathological features and prognostic significance of TAF1L in gastric cancer.BMC gastroenterology · 2024Article
- Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Novel candidate metastasis-associated genes for synovial sarcoma.Journal of cellular and molecular medicine · 2024Article
- A noninvasive nomogram model based on CT features to predict DNA mismatch repair deficiency in gastric cancer.Frontiers in oncology · 2023Article
- Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.International journal of molecular sciences · 2022Review
- The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.BMC cancer · 2022Article
- Clinical, Molecular and Genetic Characteristics of Early Onset Gastric Cancer: Analysis of a Large Multicenter Study.Cancers · 2021Article
- Mismatch repair deficiency occurs very rarely in seminomas.Translational andrology and urology · 2021Article
- The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis.Frontiers in oncology · 2021Article
- The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients.Gastroenterology research and practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microsatellite instability (MSI) tumor is one of the four molecular subtypes in gastric cancer (GC). MSI tumors are sensitive to immune checkpoint blockade therapy. However the prevalence and characteristics of MSI in GCs remains unclear. We aimed to clarify relationships between MSI and clinicopathological features along with patients' survival rates. Data was collected from a cohort of 567 consecutive GC patients who received radical gastrectomy in Fudan University Shanghai Cancer Center. Expression of four DNA mismatch repair proteins (MMRPs)-MLH1, PSM2, MSH2, MSH6 was assessed using immunohistochemistry staining. Absence of any of the four MMRPs was defined as deficiency mismatch repair (dMMR). Tumors with preserved expression of all MMRPs were considered MMR-proficient (pMMR). Chi-squared test or Fisher's exact probability test was used to detect correlation between MMR status and clinicopathological parameters. Kaplan-Meier method and Log-rank test were used for survival analysis. Fifty-seven cases (57/567, 10.1%) were confirmed as dMMR. The dMMR status was in significant correlation with older age (
Indexed as
Identifiers
31938371PMC6958290W3026433075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.